Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.

Abstract

BACKGROUND:

Prader-Willi syndrome is the most frequent genetic cause of obesity and is often complicated by glucose metabolism alterations. Conventional therapies prescribed for type 2 diabetes frequently failed to achieve adequate glycemic control in patients with Prader-Willi syndrome. Beneficial effects of glucagon like peptide-1 receptor agonists exenatide and liraglutide have been reported for the management of type 2 diabetes in Prader-Willi syndrome, but no data are currently available in this population on the use of semaglutide.

CASE PRESENTATION:

We report for the first time the use of semaglutide 1 mg per week in a 33-yearold man with Prader-Will syndrome complicated by poorly controlled diabetes and severe obesity. After 12 months of semaglutide treatment, we observed an important reduction in glycated hemoglobin levels (11.1% to 7.2%) and body weight (99.5 kg to 94.3 kg), with a notable decrease in fat mass and insulin requirements. Interestingly, our patient had already tried liraglutide therapy in adjunction to metformin and insulin therapy, reporting no substantial efficacy.

CONCLUSION:

The beneficial effects of semaglutide on glycemic control and weight reduction provide a promising treatment for diabetes and obesity in Prader-Willi syndrome, even where other glucagons like peptide-1 receptor agonists have failed. Further studies are required to confirm the efficacy and safety of semaglutide in patients with Prader-Willi syndrome.

• Authors: Elena Sani, Giuliana Da Prato, Maria Grazia Zenti, Andrea Bordugo, Maddalena Trombetta, Enzo Bonora
• Journal: Endocrine, metabolic & immune disorders drug targets (Endocr Metab Immune Disord Drug Targets) Vol. 22 Issue 10 Pg. 1053-1057 ( 2022) ISSN: 2212-3873 [Electronic] United Arab Emirates
• PMID: 35538810 (Publication Type: Case Reports)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Chemical References

• Hypoglycemic Agents
• Insulin
• semaglutide
• Glucagon-Like Peptides
• Liraglutide

Topics

• Adult
• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Glucagon-Like Peptides (pharmacology, therapeutic use)
• Glycemic Control
• Humans
• Hypoglycemic Agents (pharmacology)
• Insulin
• Liraglutide (adverse effects)
• Male
• Obesity (complications, drug therapy)
• Prader-Willi Syndrome (complications, drug therapy, metabolism)
• Weight Loss